Filing Details
- Accession Number:
- 0001209191-16-141471
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-14 19:02:47
- Reporting Period:
- 2016-09-12
- Filing Date:
- 2016-09-14
- Accepted Time:
- 2016-09-14 19:02:47
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1328143 | Adamas Pharmaceuticals Inc | ADMS | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1027621 | D Jonathan Feiber | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1129541 | Mdv Vii Lp | C/O Mohr Davidow Ventures 3000 Sand Hill Road, Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1250354 | J Nancy Schoendorf | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1410787 | Mdv Ix Lp | C/O Mohr Davidow Ventures 3000 Sand Hill Road, Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1564546 | Seventh Mdv Partners, L.l.c. | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1573991 | Ninth Mdv Partners, L.l.c. | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1605837 | Mdv Enf Vii (A), L.p. | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1605838 | Mdv Enf Vii (B), L.p. | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No | |
1605840 | Mdv Vii Leaders' Fund, L.p. | 3000 Sand Hill Road Suite 3-290 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-09-12 | 22,342 | $15.65 | 3,906,793 | No | 4 | P | Indirect | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
Common Stock | Acquisiton | 2016-09-13 | 62,034 | $15.56 | 3,968,827 | No | 4 | P | Indirect | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
No | 4 | P | Indirect | MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 265,150 | Indirect | MDV VII, L.P. |
Common Stock | 6,043 | Indirect | MDV ENF VII (A), L.P. |
Common Stock | 3,146 | Indirect | MDV ENF VII (B), L.P. |
Common Stock | 25,661 | Indirect | MDV VII Leaders' Fund, L.P. |
Common Stock | 287,992 | Indirect | MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. |
Footnotes
- Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.26 and $15.75 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Seventh MDV Partners, L.L.C. is the general partner of (i) MDV VII, L.P., as nominee for MDV VII, L.P., MDV ENF VII(A), L.P., MDV ENF VII(B), L.P., and MDV VII Leaders' Fund, L.P., (ii) MDV VII, L.P., (iii) MDV ENF VII(A), L.P., (iv) MDV ENF VII(B), L.P., and (v) MDV VII Leaders' Fund, L.P. (collectively, "MDV VII"). Feiber and Nancy Schoendorf ("Schoendorf") are Managing Members of Seventh MDV Partners, L.L.C. Feiber and Schoendorf may be deemed to share voting and dispositive power over the shares held by MDV VII. Each Reporting Person disclaims beneficial ownership of the shares held by MDV VII except to the extent of any pecuniary interest therein. Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with MDV VII. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.
- Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $15.25 and $16.00 per share. The Reporting Persons undertake to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Ninth MDV Partners, L.L.C. is the general partner of MDV IX, L.P., as nominee for MDV IX, L.P. and MDV ENF IX, L.P. (collectively, "MDV IX"). William Ericson ("Ericson") and Jonathan Feiber ("Feiber") are Managing Members of Ninth MDV Partners, L.L.C. Ericson and Feiber may be deemed to share voting and dispositive power over the shares held by MDV IX. Each Reporting Person disclaims beneficial ownership of the shares held by MDV IX except to the extent of any pecuniary interest therein. Ericson is a director of the Issuer and, accordingly, files separate Section 16 reports.